Optogenetic gene therapy holds great promise for healing blindness. Hulliger et. al. have developed a new promoter that effectively targets human ON bipolar cells. This is an important step towards clinical applications of optogenetic gene therapy for restoring vision.

Optogenetic gene therapy holds promise to restore high-quality vision in blind patients. Although the ON-bipolar cells, the first retinal interneurons, make the most attractive targets for optogenetic vision restoration, they have remained inaccessible to human gene therapy due to the lack of a robust cell-specific promoter.

We describe the design and functional evaluation of 770En_454P(hGRM6), a human GRM6 gene-derived, short promoter that drives strong and highly specific expression in both the rod- and cone-type ON-bipolar cells of the human retina. Expression also in cone-type ON-bipolar cells is of importance, since the cone-dominated macula mediates high-acuity vision and is the primary target of gene therapies. 770En_454P(hGRM6)-driven middle-wave opsin expression in ON-bipolar cells achieved lasting restoration of high visual acuity in the rd1 mouse model of late retinal degeneration.

The new promoter enables precise manipulation of the inner retinal network and paves the way for clinical application of gene therapies for high-resolution optogenetic vision restoration, raising hopes of significantly improving the life quality of people suffering from blindness.

Instructions to Join the Webinar

Key Topics Include:

  • Next-generation retinal gene therapy with AAV
  • Promoter design and evaluation
  • Human post-mortem retinal explant culturing
  • Concept of ON-bipolar cell-targeted gene therapies
  • Procedure of designing a cell-type specific promoter
  • Procedure of testing promoters in post-mortem retinal explant cultures
  • Importance of the use of adequate experimental models

Resources

Presenters

Researcher
Institute of Physiology
University of Bern

Elmar Hulliger, born in Switzerland, attained his master’s degree in Biotechnology from the ETH Zürich. Interested in applied research he subsequently joined Prof Dr. Sonja Kleinlogels Lab of Translational Optogenetics at the University of Bern for his PhD. There he established a translational model of post-mortem human retinal explant culturing and designed and evaluated synthetic promoters intended for optogenetic gene therapy. After graduating he continued his research in molecular biology and directed a pre-clinical trial of a next-generation optogenetic gene therapy.

Register

Striatech Journal Club - March 25
Tell us more about yourself:
Consent Policy *

Webinar Host

Striatech

Striatech is a young biotech company that spun off from the University of Tübingen, Germany, at the beginning of 2018. The founders – a team of neurobiologists – are all experienced vision researchers and have made it their common goal to make innovative ideas and products from vision and behavioral research accessible to scientists worldwide.

Additional Content From Striatech

Related Content